Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036894 · ClinicalTrials.gov registry record · Phase 1
CC-5013 in Treating Patients With Recurrent Glioma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00036894: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00036894 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036894, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma.
Interventions
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-03 |
| Phase | Phase 1 |
What the finished NCT00036894 record still lists
NCT00036894 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which lenalidomide is the first listed.
NCT00036894 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00036894 about?
NCT00036894 is a clinical study titled "CC-5013 in Treating Patients With Recurrent Glioma". RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma.
What is the current status of trial NCT00036894?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-03.
What interventions are being tested in trial NCT00036894?
The interventions under investigation include: lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00036894?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia